Sinha V R, Singh Asmita, Singh Sanjay, Bhinge J R
Pharmaceutics Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.
J Pharm Pharmacol. 2007 Mar;59(3):359-65. doi: 10.1211/jpp.59.3.0004.
Compression coating is one of the approaches for delaying the release of drugs. The aim of this study was to develop colon-specific compression coated systems of 5-fluorouracil (5-FU) for the treatment of colorectal cancer using xanthan gum, boswellia gum and hydroxypropyl methylcellulose (HPMC) as the coating materials. Core tablets containing 50 mg of 5-FU were prepared by direct compression. The coating of the core tablets was done using different coat weights (230, 250, 275 and 300 mg) and different ratios (1:2, 2:1, 1:3, 1:7 and 3:4) of boswellia gum and xanthan gum and different ratios (1:1, 1:2, 2:1, and 2:3) of boswellia gum and HPMC. In-vitro release studies were carried out using simulated gastric and intestinal fluids, with and without rat caecal contents. Among the different ratios used for coating with boswellia:xanthan gum combination, ratio 1:3 gave the best release profile with the lowest coating weights of 230 mg (7.47 +/- 1.56% in initial 5 h). Further increase in the coat weights to 250, 275 and 300 mg led to drug release of 5.63 +/- 0.53%, 5.09 +/- 1.56% and 4.57 +/- 0.88%, respectively, in the initial 5 h and 96.90 +/- 0.66%, 85.05 +/- 1.01% and 80.22 +/- 0.35%, respectively, in 24 h. When coating was carried out using different ratios of the combination boswellia gum and HPMC, the ratio 2:3 gave the best results among the initial trial batches (7.80 +/- 0.57% in 5 h). Increasing the coat weights to 250, 275 and 300 mg led to drug release of 6.5 +/- 0.27%, 3.70 +/- 2.3% and 2.99 +/- 0.72%, respectively, in the initial 5 h and 96.90 +/- 0.66%, 85.05 +/- 1.01% and 80.22 +/- 0.35%, respectively, in 24 h. In-vitro studies were further carried out in the presence of 2% w/v rat caecal contents, which led to complete release of the drug from the tablets. Therefore, this study lays a basis for use of compression coating of 5-FU as a tool for delaying the release of the drug, which ensures better clinical management of the disease.
包衣压制是延缓药物释放的方法之一。本研究的目的是开发以黄原胶、乳香胶和羟丙基甲基纤维素(HPMC)为包衣材料的5-氟尿嘧啶(5-FU)结肠特异性包衣压制系统,用于治疗结直肠癌。通过直接压片制备含50mg 5-FU的片芯。片芯包衣采用不同的包衣重量(230、250、275和300mg)、不同比例(1:2、2:1、1:3、1:7和3:4)的乳香胶和黄原胶以及不同比例(1:1、1:2、2:1和2:3)的乳香胶和HPMC。使用模拟胃液和肠液,在有和没有大鼠盲肠内容物的情况下进行体外释放研究。在用于乳香胶与黄原胶组合包衣的不同比例中,1:3的比例在最低包衣重量230mg时具有最佳释放曲线(最初5小时内为7.47±1.56%)。将包衣重量进一步增加到250、275和300mg时,最初5小时内的药物释放分别为5.63±0.53%、5.09±1.56%和4.57±0.88%,24小时内分别为96.90±0.66%、85.05±1.01%和80.22±0.35%。当使用乳香胶与HPMC组合的不同比例进行包衣时,在最初的试验批次中2:3的比例效果最佳(5小时内为7.80±0.57%)。将包衣重量增加到250、275和300mg时,最初5小时内的药物释放分别为6.5±0.27%、3.70±2.3%和2.99±0.72%,24小时内分别为96.90±0.66%、85.05±1.01%和80.22±0.35%。在含有2%w/v大鼠盲肠内容物的情况下进一步进行体外研究,结果导致药物从片剂中完全释放。因此,本研究为将5-FU包衣压制作为延缓药物释放的工具奠定了基础,这确保了对该疾病更好的临床管理。